secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001140361-23-014662
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys reports 2022 net loss of $11.4M, revenue up 2.2% to $1.2M
-----------------------------------------------------------------

- Net loss of $11.4M ($0.96 per share) vs $7.5M loss in 2021; cash $12.96M expected to fund into Q1 2024.
- Revenue $1.21M (+2.2% YoY); gross margin fell to 63.4% from 68.6%.
- R&D expenses rose 42% to $5.81M; G&A expenses rose 27% to $5.43M.
- Commercial launches of FemCath (tubal evaluation) and FemCerv (tissue sampler) in late 2022.
- Clinical progress: FemBloc Stage 2 enrollment complete; FemaSeed pivotal trial 25% enrolled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036123014662/0001140361-23-014662-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036123014662/brhc10050619_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-014662

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer